QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, March 4, 2009, 29(9):2824-2832; doi:10.1523/JNEUROSCI.6186-08.2009

This Article Full Text Full Text (PDF) Supplemental Data Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Uo, T. Articles by Morrison, R. S. Search for Related Content PubMed PubMed Citation Articles by Uo, T. Articles by Morrison, R. S.

 Previous Article  |  Next Article 

Cellular/Molecular
Histone Deacetylase Inhibitors Prevent p53-Dependent and p53-Independent Bax-Mediated Neuronal Apoptosis through Two Distinct Mechanisms

Takuma Uo,¹ Timothy D. Veenstra,² and Richard S. Morrison¹

¹Department of Neurological Surgery, University of Washington School of Medicine, Seattle, Washington 98195-6470, and ²Laboratory of Proteomics and Analytical Technologies, Science Applications International Corporation-Frederick, Inc., National Cancer Institute at Frederick, Frederick, Maryland 21702-1201

Correspondence should be addressed to Dr. Richard S. Morrison, Department of Neurological Surgery, University of Washington School of Medicine, Box 356470, Seattle, WA 98195-6470. Email: yael{at}u.washington.edu

Pharmacological manipulation of protein acetylation levels by histone deacetylase (HDAC) inhibitors represents a novel therapeutic strategy to treat neurodegeneration as well as cancer. However, the molecular mechanisms that determine how HDAC inhibition exerts a protective effect in neurons as opposed to a cytotoxic action in tumor cells has not been elucidated. We addressed this issue in cultured postnatal mouse cortical neurons whose p53-dependent and p53-independent intrinsic apoptotic programs require the proapoptotic multidomain protein, Bax. Despite promoting nuclear p53 accumulation, Class I/II HDAC inhibitors (HDACIs) protected neurons from p53-dependent cell death induced by camptothecin, etoposide, heterologous p53 expression or the MDM2 inhibitor, nutlin-3a. HDACIs suppressed p53-dependent PUMA expression, a critical signaling intermediate linking p53 to Bax activation, thus preventing postmitochondrial events including cleavage of caspase-9 and caspase-3. In human SH-SY5Y neuroblastoma cells, however, HDACIs were not able to prevent p53-dependent cell death. Moreover, HDACIs also prevented caspase-3 cleavage in postnatal cortical neurons treated with staurosporine, 3-nitropropionic acid and a Bcl-2 inhibitor, all of which require the presence of Bax but not p53 to promote apoptosis. Although these three toxic agents displayed a requirement for Bax, they did not promote PUMA induction. These results demonstrate that HDACIs block Bax-dependent cell death by two distinct mechanisms to prevent neuronal apoptosis, thus identifying for the first time a defined molecular target for their neuroprotective actions.

---

Received Dec. 30, 2008; revised Jan. 29, 2009; accepted Jan. 30, 2009.

Correspondence should be addressed to Dr. Richard S. Morrison, Department of Neurological Surgery, University of Washington School of Medicine, Box 356470, Seattle, WA 98195-6470. Email: yael{at}u.washington.edu

This article has been cited by other articles:

				E. Kim and J. Shohet Targeted Molecular Therapy for Neuroblastoma: The ARF/MDM2/p53 Axis J Natl Cancer Inst, November 18, 2009; 101(22): 1527 - 1529. [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help